We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
68.00 | 0.56% | 12,118.00 | 12,120.00 | 12,124.00 | 12,162.00 | 11,966.00 | 11,966.00 | 2,561,221 | 16:35:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.56 | 187.91B |
By Razak Musah Baba
LONDON--AstraZeneca PLC (AZN.LN) has agreed to sell the U.S. rights to Crohn's disease treatment Entocort to Perrigo Company PLC (PRGO) for $380 million.
AstraZeneca, the U.K-based pharmaceutical group which is selling off non-core assets, said on Monday that Perrigo will also acquire authorized generic Entocort capsules marketed by Par Pharmaceuticals. The drug is a gastroenterology medicine for patients with mild to moderate Crohn's disease.
"Our agreement with Perrigo completes the global divestment of Entocort, emphasizing our strategic focus on three main therapy areas and providing further simplification of our supply chain," Luke Miels, an AstraZeneca executive vice president.
AstraZeneca had previously sold the rights to the drug outside the U.S. to Tillotts Pharma AG.
The latest transaction is expected to complete by the end of 2015.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 23, 2015 02:49 ET (07:49 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions